Scrip
ViiV's Selzentry approved for treatment-naive HIV patients in US
24 November 2009
Katie McQue
Please Login to read the full article.
24 November 2009
Katie McQue
The US FDA has approved a label expansion of ViiV Healthcare's CCR5 antagonist Selzentry (maraviroc) to include treatment-naive HIV patients.
The move follows an endorsement last month by an FDA advisory panel for use of the drug in this patient population.
The label expansion also...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
